The Unrecognized Burden of RSV in Older Adults

Respiratory Syncytial Virus (RSV) is associated with substantial morbidity and mortality in older adults with a disease burden comparable to influenza. Advancing age increases susceptibility and mortality to RSV-associated pneumonia and the presence of underlying comorbidities—such as CHF and COPD—increases the risk of hospitalization among older adults who develop RSV.

This webinar will discuss how to clinically recognize and diagnose RSV in older adults, as well as review new therapies and vaccines for RSV.

Learning Objectives:

By the end of the webinar, participants should be able to:

  • Define the burden of RSV in older adults.
  • Explain how to clinically recognize and diagnose RSV.
  • Discuss the latest therapies and vaccines for RSV.

Angela Branche, MD

Angela Branche, MD, is an Associate Professor of Medicine at the University of Rochester. Dr. Branche received her Bachelor of Arts degree in Biology at the University of Pennsylvania and Doctorate in Medicine at American University of the Caribbean. She completed residency in Internal Medicine at NYU Langone Hospital-Brooklyn in Brooklyn, NY and infectious disease fellowship at the University of Rochester. She currently has a clinical inpatient practice comprised of both general infectious diseases and HIV medicine patients. During her years at the University of Rochester her focus in research involved the use of viral molecular and immunological diagnostic assays to explore the pathogenesis and host response to acute viral respiratory illnesses in adults. She is currently Co-Principle Investigator for the UR Vaccine Treatment and Evaluation Unit (UR VTEU) one of ten NIH funded network sites in the US. Her current research activities explore clinical disease, pathogenesis, development of therapeutics and vaccine biology related to infection with viral and bacterial respiratory pathogens. Studies include population-based studies of RSV infection and the development of vaccines and anti-viral agents for RSV. She is actively involved in the NIH and University of Rochester research response to COVID-19 and is helping conduct, natural history, therapeutic and vaccine studies. She is a member of the Infectious Disease Society of America Public Health Committee and  the NIH IDCRC Emerging Infections Expert Working Group.  

Ghinwa Dumyati, MD

Ghinwa Dumyati, MD, is an infectious disease physician and professor of medicine at the University of Rochester Medical Center. Her research, which is presently funded by the Centers for Diseases Control and Prevention, focuses on emerging infectious diseases of public health importance. She is also an expert in quality improvement and antibiotic stewardship and has assisted numerous nursing homes in implementing antibiotic stewardship programs. She is the chair of the AMDA Infection Advisory Subcommittee and a Fellow of the Society of Healthcare Epidemiology of America.

  • 1.0 CME
  • 1.0 CMD Clinical 

Release Date: 07/27/2023   |   Expiration: 07/27/2026

Credit Statements:

Accreditation: Post-Acute and Long-Term Care Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  

CME Designation: Post-Acute and Long-Term Care Medical Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CMD Credit Hours: This CME activity has been pre-approved by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) for up to 1.0 clinical hour(s) toward certification or recertification as a Certified Medical Director (CMD) in post-acute and long-term care medicine. Each physician should claim only those hours of credit actually spent on the activity. 

The CMD Program is administered by the ABPLM. For further information, contact ABPLM at 410-992-3117 or at cmd@paltmed.org. 

Financial Disclosure Statement:

  • The following PALTmed Education Committee members have financial relationships to report: Diane Sanders-Cepeda, DO, CMD — UHG-Optum: Full-Time Employee; all others have no relationships with ineligible companies.
  • The following speaker has financial relationships to report: Angela Branche, MD  –  GSK, Janssen: Advisory Board; Pfizer, Cyanvac, Vaccine.Com, Merck: Grant/Research Support (principal investigators); Ghinwa Dumyati, MD  –  Pfizer: Contracted Research (Principal Investigators must provide information, even if received by the institution)

No one else in control of content disclosed a relevant financial relationship with an ineligible company. All relevant financial relationships have been identified, mitigated, and resolved.

Components visible upon registration.